New ACP3 scan could spot prostate cancer better
NCT ID NCT07559201
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a new type of PET/CT scan that targets a protein called ACP3 to find prostate cancer tumors. Researchers will compare it to standard PSMA/FDG scans in 100 adults with newly diagnosed or recurrent prostate cancer. The goal is to see if the ACP3 scan is more accurate at detecting cancer lesions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ACP3 PET/CT scan
- What this could lead to
- If successful, this could provide a more accurate imaging method for detecting prostate cancer, potentially improving diagnosis and treatment planning.
- What could go wrong
- This is an early-stage diagnostic study with 100 participants, so results may not apply to all patients. The new scan may not be more accurate than current methods.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER (DIAGNOSIS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affliated Hospital of Guilin Medical University
RECRUITINGGuilin, Guangxi, 541001, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A sharper eye on prostate cancer return: PSMA PET vs. MRI
- AI may help spot dangerous prostate cancer and spare men from needless biopsies
- Blood test may spot prostate cancer without a needle
- AI reads scans to spot prostate cancer, spare unnecessary biopsies
- Extra numbing shot may ease pain of prostate biopsy
- Community-Led push to catch prostate cancer early in black men